Cytokinetics

CYTK · NASDAQ

$63.95+$1.30 (+2.08%)TodayMarket closed · Oct 20, 6:27 PM ET

Prev close $62.65

Latest news

Press releaseOct 19, 4:00 PM ETGlobe Newswire
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseOct 19, 7:30 AM ETGlobe Newswire
Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Press releaseOct 12, 4:00 PM ETGlobe Newswire
Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026
NewsOct 12, 7:25 AM ET
Cytokinetics Q2 2026 Earnings Call: Complete Transcript
Press releaseOct 2, 7:30 AM ETGlobe Newswire
Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026
Press releaseSep 30, 7:30 AM ETGlobe Newswire
Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy
NewsSep 25, 4:19 PM ETChandrima Sanyal
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach
Press releaseSep 17, 4:00 PM ETGlobe Newswire
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewsAug 31, 1:43 PM ETVandana Singh
Cytokinetics Investors Weigh Safety Data From Pivotal Trial
Press releaseAug 29, 10:30 AM ETGlobe Newswire
Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026
Press releaseAug 28, 5:45 AM ETGlobe Newswire
Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine
Press releaseAug 6, 4:00 PM ETGlobe Newswire
Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
NewsJul 24, 3:08 PM ETChandrima Sanyal
New AI ETF Bets on Healthcare's $9 Trillion Opportunity
Press releaseJul 23, 4:00 PM ETGlobe Newswire
Cytokinetics to Announce Second Quarter Results on August 6, 2026
Press releaseMay 5, 4:05 PM ETGlobe Newswire
Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update
NewsMay 5, 10:48 AM ETVandana Singh
Cytokinetics Stock Rallies After Pivotal Heart Disease Study Hits Dual Primary Endpoints
NewsMay 5, 8:06 AM ET
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
NewsMay 5, 7:12 AM ET
Earnings Scheduled For May 5, 2026
NewsMay 1, 1:35 PM ET
10 Health Care Stocks With Whale Alerts In Today's Session
Press releaseApr 21, 4:00 PM ETGlobe Newswire
Cytokinetics to Announce First Quarter Results on May 5, 2026
NewsFeb 24, 4:08 PM ET
Cytokinetics Q4 Earnings Summary & Key Takeaways
Press releaseFeb 24, 4:00 PM ETGlobe Newswire
Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
NewsFeb 23, 11:02 AM ET
Preview: Cytokinetics's Earnings
Press releaseJan 27, 8:00 AM ETGlobe Newswire
Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)
Press releaseJan 27, 7:30 AM ETGlobe Newswire
Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
Press releaseJan 22, 2:39 PM ETBusiness Wire
The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors
Press releaseJan 8, 8:59 AM ETGlobe Newswire
Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf
Press releaseDec 30, 9:57 AM ETGlobe Newswire
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. (NYSE: MOH); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
NewsDec 24, 10:21 AM ETVandana Singh
Why Is Edgewise Therapeutics Stock Soaring Wednesday?
NewsDec 22, 11:23 AM ETVandana Singh
Cytokinetics Wins FDA Nod For Heart Drug Myqorzo
NewsDec 22, 7:38 AM ET
Market-Moving News for December 22nd
Press releaseDec 16, 8:40 AM ETGlobe Newswire
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf
Press releaseDec 12, 2:37 PM ETGlobe Newswire
Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
Press releaseDec 9, 9:18 AM ETGlobe Newswire
Notice For Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. (NYSE: MOH); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims on Your Behalf
Press releaseDec 8, 8:35 AM ETGlobe Newswire
Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
Press releaseDec 4, 12:05 PM ETGlobe Newswire
Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. (NYSE: MOH); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf
Press releaseNov 17, 7:39 PM ETPRNewswire
CYTK Deadline: CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
Press releaseNov 17, 11:14 AM ETBusiness Wire
CYTK FINAL DEADLINE: Faruqi & Faruqi, LLP Announces that Cytokinetics Investors Have Opportunity to Lead Class Action Lawsuit
Press releaseNov 17, 8:45 AM ETPRNewswire
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cytokinetics, Incorporated (CYTK) Shareholders
Press releaseNov 14, 6:23 PM ETBusiness Wire
Cytokinetics 72 Hour Deadline Alert: Former Louisiana Attorney General And Kahn Swick & Foti, LLC Remind Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Cytokinetics, Incorporated - CYTK
Press releaseNov 14, 12:00 PM ETPRNewswire
Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Press releaseNov 14, 11:19 AM ETGlobe Newswire
Bragar Eagel & Squire, P.C. Urgently Reminds Investors of Cytokinetics, Quanex, Freeport, and Primo Brands to Contact the Firm About their Rights
Press releaseNov 14, 10:16 AM ETPRNewswire
CYTK DEADLINE: Faruqi & Faruqi Reminds Cytokinetics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 17, 2025 - CYTK
Press releaseNov 14, 9:00 AM ETPRNewswire
Cytokinetics, Incorporated Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights - CYTK
Press releaseNov 14, 3:06 AM ETPRNewswire
CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm
Press releaseNov 14, 3:00 AM ETPRNewswire
Cytokinetics, Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CYTK

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026

Cytokinetics Q2 2026 Earnings Call: Complete Transcript

Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026

Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics Investors Weigh Safety Data From Pivotal Trial

Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026

Cytokinetics Announces Positive Results from ACACIA-HCM Presented in Hot Line Session at the European Society of Cardiology (ESC) Congress 2026 and Published in The New England Journal of Medicine

Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update

New AI ETF Bets on Healthcare's $9 Trillion Opportunity

Cytokinetics to Announce Second Quarter Results on August 6, 2026

Cytokinetics Reports First Quarter 2026 Financial Results and Provides Business Update

Cytokinetics Stock Rallies After Pivotal Heart Disease Study Hits Dual Primary Endpoints

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Earnings Scheduled For May 5, 2026

10 Health Care Stocks With Whale Alerts In Today's Session

Cytokinetics to Announce First Quarter Results on May 5, 2026

Cytokinetics Q4 Earnings Summary & Key Takeaways

Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update

Preview: Cytokinetics's Earnings

Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM)

Cytokinetics Announces MYQORZO™ (aficamten) Now Available in the U.S. for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms

The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors

Important Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Lifecore Biomedical, Inc. (NASDAQ: LFCR); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf

Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. (NYSE: MOH); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment, Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf

Why Is Edgewise Therapeutics Stock Soaring Wednesday?

Cytokinetics Wins FDA Nod For Heart Drug Myqorzo

Market-Moving News for December 22nd

Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Molina Healthcare, Inc. (NYSE: MOH); and Synopsys, Inc. (NASDAQ: SNPS): Grabar Law Office Investigates Claims on Your Behalf

Notice to Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf

Notice For Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. (NYSE: MOH); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office is Investigating Claims on Your Behalf

Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Fortrea Holdings, Inc. (NASDAQ: FTRE); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf

Attention Long-Term Shareholders of Cytokinetics, Inc. (NASDAQ: CYTK); Molina Healthcare, Inc. (NYSE: MOH); Synopsys, Inc. (NASDAQ: SNPS); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates Claims on Your Behalf

CYTK Deadline: CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit

CYTK FINAL DEADLINE: Faruqi & Faruqi, LLP Announces that Cytokinetics Investors Have Opportunity to Lead Class Action Lawsuit

The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Cytokinetics, Incorporated (CYTK) Shareholders

Cytokinetics 72 Hour Deadline Alert: Former Louisiana Attorney General And Kahn Swick & Foti, LLC Remind Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Cytokinetics, Incorporated - CYTK

Cytokinetics, Incorporated (CYTK) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

Bragar Eagel & Squire, P.C. Urgently Reminds Investors of Cytokinetics, Quanex, Freeport, and Primo Brands to Contact the Firm About their Rights

CYTK DEADLINE: Faruqi & Faruqi Reminds Cytokinetics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 17, 2025 - CYTK

Cytokinetics, Incorporated Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights - CYTK

CYTK Investors Have Opportunity to Lead Cytokinetics, Incorporated Securities Fraud Lawsuit with the Schall Law Firm

Cytokinetics, Incorporated Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CYTK